Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 4:12:1537707.
doi: 10.3389/fnut.2025.1537707. eCollection 2025.

C-reactive protein to high-density lipoprotein cholesterol ratio: an independent risk factor for diabetic retinopathy in type 2 diabetes patients

Affiliations

C-reactive protein to high-density lipoprotein cholesterol ratio: an independent risk factor for diabetic retinopathy in type 2 diabetes patients

Yuan Zhang et al. Front Nutr. .

Abstract

Background and objective: Diabetic retinopathy (DR) is associated with abnormal lipid metabolism and inflammation. However, a single lipid or inflammatory parameter cannot accurately predict the prognosis of DR independently, because it is prone to be affected by various confounding factors. This study aimed to explore the relationship between the inflammation-lipid indicator C-reactive protein (CRP)/high-density lipoprotein cholesterol (HDL-C) and DR occurrence in subjects with type 2 diabetes mellitus (T2DM).

Methods: This hospital-based retrospective study included 784 T2DM patients. Diabetic retinopathy was diagnosed by nonmydriatic fundus photography and/or fundus examination apparatus. T2DM patients were divided into non-DR and DR groups. Demographics variables, clinical history and serum biochemical indicators of the subjects were collected. We also calculated the CRP/HDL-C ratio. The association between the CRP/HDL-C and DR was assessed using multivariate logistic regression analyses.

Results: A total of 784 participants, 612 without DR and 172 with DR, were included in the final sample analysis. Compared with non-DR participants, the DR diagnostic group had significantly higher CRP/HDL-C (4.03 ± 1.67 vs. 2.66 ± 0.97; p < 0.001). Then, the patients were grouped based on the quartiles of CRP/HDL-C, there was a gradual increase in the prevalence of DR was noted in T2DM patients along with the increased quartile of the CRP/HDL-C ratio (Q1: 7.65%; Q2: 15.31%; Q3: 19.90%; Q4: 44.90%; p = 0.028). After adjustment for the impact of various covariates, the odds ratio (OR) of the third and fourth vs. the first quartile of CRP/HDL-C were 2.905 (95% confidence interval [CI]: 1.372 ~ 6.152, p = 0.005) and 9.938 (95% CI: 4.987 ~ 19.804, p < 0.001), respectively. Further, multivariate logistic regression model showed that the CRP/HDL-C ratio (OR 3.176, 95% CI: 1.280 ~ 7.877, p = 0.013) was identified as risk factor for DR. Moreover, the area under the curve (AUC) to evaluate the predictive value of CRP/HDL-C for the risk of DR occurrence was 0.752 (95% CI: 0.711 ~ 0.794).

Conclusion: The ratio of C-reactive protein (CRP) to high-density lipoprotein cholesterol (HDL-C) is associated with DR in patients with T2DM, and CRP/HDL-C may be an effective marker to help identify the risk of DR in patients with T2DM.

Keywords: biomarker; diabetic retinopathy (DR); dyslipidemia; inflammation; the CRP to HDL-C ratio; type 2 diabetes mellitus (T2DM).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Receiver operating characteristic curves (ROC) of DR in T2DM. (A) CRP/HDL-C; (B) CRP/HDL-C combined other 4-indicators (Age, Duration, FPG, and HbA1c).

Similar articles

References

    1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. . IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. (2022) 183:109119. doi: 10.1016/j.diabres.2021.109119, PMID: - DOI - PMC - PubMed
    1. Zayed MG, Karsan W, Peto T, Saravanan P, Virgili G, Preiss D. Diabetic retinopathy and quality of life: a systematic review and Meta-analysis. JAMA Ophthalmol. (2024) 142:199–207. doi: 10.1001/jamaophthalmol.2023.6435, PMID: - DOI - PMC - PubMed
    1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. (2010) 376:124–36. doi: 10.1016/S0140-6736(09)62124-3 - DOI - PubMed
    1. Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. . Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and Meta-analysis. Ophthalmology. (2021) 128:1580–91. doi: 10.1016/j.ophtha.2021.04.027, PMID: - DOI - PubMed
    1. Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. (2018) 19:1816. doi: 10.3390/ijms19061816, PMID: - DOI - PMC - PubMed

LinkOut - more resources